OZ Stoners Posted March 19, 2013 Report Share Posted March 19, 2013 LONDON (Reuters) - GW Pharmaceuticals and Almirall may stop selling the cannabis drug Sativex in Germany after health authorities refused to agree a price that the companies view as acceptable. GW - which developed the under-the-tongue spray as a treatment for spasticity in multiple sclerosis - said on Tuesday the German authorities had determined a price that was significantly lower than in ... View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.